Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, Padua, Italy.
Best Pract Res Clin Rheumatol. 2011 Oct;25(5):637-48. doi: 10.1016/j.berh.2011.10.013.
Bartter's and Gitelman's syndromes are two different genetic renal diseases, but are both characterised by hypokalaemia and metabolic alkalosis. Bartter's syndrome is characterised by multiple gene mutations (Na-K-2Cl cotransporter; K(+) channels renal outer medullary potassium channel (ROMK); Cl channels, chloride channel Kb (ClCNKb); regulatory protein Barttin; and Ca(2+) -sensing receptor, CaSR) at the thick ascending limb of Henle's loop, while Gitelman's syndrome is caused by a mutation in the gene encoding the renal thiazide sensitive Na(+)-Cl(-) cotransporter, located in the apical membrane of the distal convoluted tubule. The co-existence of hypokalaemia with hypomagnesaemia and hypocalciuria represents the biochemical hallmark of Gitelman's syndrome that distinguishes it from Bartter's syndrome. Calcium pyrophosphate deposition (CPPD) including chondrocalcinosis has been frequently reported in association with Bartter's syndrome. Some authors postulate that these cases were probably due to Gitelman's syndrome and not due to Bartter's syndrome as all patients had hypomagnesaemia. This electrolyte disorder seems to induce CCP crystal deposition. To date, no cases of CPPD have been reported in patients who had Bartter's syndrome without hypomagnesaemia. CPPD may be found in other conditions associated with hypomagnesaemia, such as short bowel syndrome or tacrolimus therapy in liver transplantation patients. As acute CPP crystal arthropathy or pseudogout can be the onset presentation of Gitelman's syndrome, CPPD should be considered a major feature of this disease. Rheumatologists should be aware of the association between Gitelman's syndrome and CPPD, and should consider this metabolic disorder when CPPD occurs in younger patients.
巴特氏症候群和吉特曼氏症候群是两种不同的遗传性肾脏疾病,但都以低钾血症和代谢性碱中毒为特征。巴特氏症候群的特征是在亨利氏袢升支粗段的多个基因突变(钠-钾-2 氯协同转运蛋白;钾通道肾脏外髓质钾通道(ROMK);氯通道,氯离子通道 Kb(ClCNKb);调节蛋白 Barttin;和钙敏感受体,CaSR),而吉特曼氏症候群是由于编码位于远端卷曲小管腔侧顶端膜的噻嗪敏感的钠-氯协同转运体的基因突变引起的。低钾血症伴低镁血症和低钙尿症的共存代表了吉特曼氏症候群的生化特征,使其与巴特氏症候群区分开来。焦磷酸钙沉积(CPPD)包括软骨钙素已被频繁报道与巴特氏症候群有关。一些作者假设这些病例可能是由于吉特曼氏症候群而不是由于巴特氏症候群引起的,因为所有患者都有低镁血症。这种电解质紊乱似乎会诱导 CCP 晶体沉积。迄今为止,在没有低镁血症的巴特氏症候群患者中尚未报告 CPPD 病例。CPPD 可能在其他与低镁血症相关的疾病中发现,如短肠综合征或肝移植患者中他克莫司治疗。由于急性 CPP 晶体关节病或假性痛风可能是吉特曼氏症候群的发病表现,CPPD 应被视为该疾病的主要特征。风湿病学家应该意识到吉特曼氏症候群和 CPPD 之间的关联,并且应该在 CPPD 发生在年轻患者时考虑这种代谢紊乱。